Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A3ENQ51
Tue, 12.08.2025
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma delivers solid final third-quarter results
Q3 2025 revenues up 1% yoy to EUR 256m; increase of 3% yoy at constant currencies
Q3 2025 EBITDA margin of 32.4% as reported and 31.7% at constant currencies
Share of strong-margin high-value solutions (HVS) at 60% in Q3 2025
Organic revenue growth for FY 2025 is expected to be around 6. [ … ]
Tue, 05.08.2025
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma reports preliminary results for Q3 2025 and specifies FY 2025 guidance
Q3 2025 revenues up 3% yoy at constant currencies to EUR 256m
Q3 2025 EBITDA up 11% yoy to EUR 83m, with a quarterly margin of 32.4% (31.7% at constant currencies)
Organic revenue growth for FY 2025 is expected to be around 6.0%, at the lower end of management e [ … ]
Tue, 05.08.2025
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma specifies FY 2025 guidance for revenue growth and EBITDA margin
SCHOTT Pharma specifies FY 2025 guidance:
Organic revenue growth for FY 2025 is expected to be around 6.0%, at the lower end of management expectations between 6.0% and 9.0% (“high-single digit”).
The EBITDA margin for FY 2025 is expected to be around 28.0%, above the p [ … ]
Wed, 11.06.2025
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma Supervisory Board extends contract of CEO Andreas Reisse and appoints Reinhard Mayer as new CFO
Andreas Reisse’s contract as CEO of SCHOTT Pharma extended
CFO Dr. Almuth Steinkühler to leave the company at her own request to pursue new professional opportunities
Reinhard Mayer appointed as new CFO of SCHOTT Pharma
The Supervisory B [ … ]
Wed, 04.06.2025
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma invests in sterile cartridge production in Hungary
June 4, 2025, Hungary, Lukácsháza
SCHOTT Pharma breaks ground for a new production facility for ready-to-use cartridges in Hungary
Its investment of over EUR 100 million is part of the company’s expansion strategy to meet the growing market demand for high-value solutions
The new [ … ]
Thu, 15.05.2025
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma delivers strong second quarter of fiscal year 2025
Q2 2025 revenues up 8% yoy to EUR 252m; increase of 10% yoy at constant currencies
Q2 2025 EBITDA margin of 28.6% as reported and 28.2% at constant currencies
Share of strong-margin high-value solutions (HVS) at 56% in Q2 2025
SCHOTT Pharma reaffirms FY 2025 guidance
SCHOTT Pharma [ … ]
Tue, 06.05.2025
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma and Serum Institute of India welcome new partner to Joint Venture in India; TPG makes strategic investment in SCHOTT Poonawalla
TPG, a leading global alternative asset management firm will acquire 35% stake in SCHOTT Poonawalla from Serum Institute of India (SII)
SII will retain a minority stake in the company, with SCHOTT Pharma [ … ]
Thu, 10.04.2025
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma: Preliminary Q2 2025 figures exceed capital market expectations
Based on preliminary figures, SCHOTT Pharma expects an increase in sales, EBITDA and EBITDA margin in the second quarter of 2025 (as of March 31, 2025). The company expects Q2 2025 revenues of EUR 252m, corresponding to a year-over-year growth of 10% at constant currenc [ … ]
Thu, 10.04.2025
SCHOTT Pharma AG & Co. KGaA
Next expansion milestone achieved: SCHOTT Pharma opens production facility in Serbia to strengthen competitiveness in Europe
April 10, 2025, Jagodina, Serbia
After a double-digit million euro investment and less than 1.5 years of construction, SCHOTT Pharma opens new manufacturing site in Jagodina, Serbia
Production capacity to meet European mar [ … ]
Thu, 13.02.2025
SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma records good start into fiscal year and confirms full year outlook
Q1 2025 revenues reached EUR 230m; decrease of 1% yoy as reported or increase of 4% at constant currencies
Q1 2025 EBITDA margin of 25.1% as reported or 26.3% at constant currencies
Share of strong-margin high-value solutions (HVS) further increased to 55%
Busines [ … ]
